Bob Carter, deputy director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases
Heres what that may look like for each medication: Semaglutide: Weeks 1-4: 0.25 mg/week Weeks 5-8: 0.5 mg/week Weeks 9-12: 1.0 mg/week Weeks 13-16: 1.75 mg/week Week 17 and beyond: 2.5 mg/week Tirzepatide: Weeks 1-4: 2.5 mg/week Weeks 5-8: 5.0 mg/week Weeks 9-12: 7.5 mg/week Weeks 13-16: 10 mg/week In some cases, patients may increase to 12.5 mg or 15 mg per week if needed
One exception, we could find, is a study that found that topically applied ALA has nice spot-fading abilities
A treatment strategy based on stricter glucose control, intended to reduce glycated hemoglobin (HbA1c) levels to close to those of a person without diabetes, has been shown to reduce mortality and the appearance of micro- and macrovascular complications in people with DM (46)
10.1007/s11481-013-9473-5 J
Following the exclusion of reports with incomplete methodologies, 93 studies were ultimately selected for comprehensive analysis